Polyamyna develops advanced antimicrobial technologies to combat multi-extensive and pan-drug-resistant pathogenic microorganisms.
Polyamyna has raised $354K in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2023.
Polyamyna's investors include Government of Newfoundland and Labrador, Genesis, National Research Council of Canada Industrial Research Assistance Program, Sustainable Development Technology Canada.
Polyamyna is headquartered in St. John's, Canada.
Polyamyna develops advanced antimicrobial technologies to combat multi-extensive and pan-drug-resistant pathogenic microorganisms.
Polyamyna is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Polyamyna — Funding & Investors." VCBacked, September 5, 2023, https://www.vcbacked.co/company/polyamyna. Accessed August 13, 2026.
VCBacked. (2023). Polyamyna — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/polyamyna
{{cite web |title=Polyamyna — Funding & Investors |url=https://www.vcbacked.co/company/polyamyna |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated